SCHEMBL4995331

SCHEMBL4995331

CCN(CC)CC(C)Nc1ccc(NC=C2C(=O)Nc3ccccc32)cc1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.36
PDGFRB P09619 4/20 0.36
FGFR1 P11362 3/20 0.36
PRKAA2 P54646 1/20 0.36
PRKAA1 Q13131 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
ALK Q9UM73 5/20 0.35
MAPT P10636 5/20 0.34
ALDH1A1 P00352 3/20 0.34
NPSR1 Q6W5P4 3/20 0.34
LMNA P02545 2/20 0.34
TGM2 P21980 1/20 0.34
HTT P42858 1/20 0.34
IDO1 P14902 1/20 0.34
EGFR P00533 3/20 0.34
ERBB2 P04626 3/20 0.34
IGF1R P08069 3/20 0.34
GLB1 P16278 1/20 0.34
CTRC Q99895 1/20 0.34
NOX4 Q9NPH5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4995327 1.00 KDR (0.36) KDRPDGFRBFGFR1PRKAA2PRKAA1
SCHEMBL4987031 0.91 SMN1; SMN2 (0.39) PDGFRBSMN1; SMN2ALKMAPTALDH1A1
SCHEMBL4987041 0.91 SMN1; SMN2 (0.39) PDGFRBSMN1; SMN2ALKMAPTALDH1A1
SCHEMBL4993488 0.90 FLT3 (0.42) KDRPDGFRBFGFR1PRKAA2PRKAA1
SCHEMBL4993486 0.90 FLT3 (0.42) KDRPDGFRBFGFR1PRKAA2PRKAA1
SCHEMBL4992138 0.90 KDR (0.40) KDRPDGFRBFGFR1PRKAA2PRKAA1
SCHEMBL4992134 0.90 KDR (0.40) KDRPDGFRBFGFR1PRKAA2PRKAA1
SCHEMBL4995323 0.88 ALK (0.39) KDRPDGFRBFGFR1PRKAA2PRKAA1
SCHEMBL4995334 0.88 ALK (0.39) KDRPDGFRBFGFR1PRKAA2PRKAA1
SCHEMBL4999234 0.87 PDGFRB (0.39) KDRPDGFRBEGFRFLT3NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 KDR 256/4885PDGFRB 307/4885FGFR1 346/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 KDR 256/4885PDGFRB 307/4885FGFR1 346/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 KDR 256/4885PDGFRB 307/4885FGFR1 346/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 KDR 256/4885PDGFRB 307/4885FGFR1 346/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 KDR 256/4885PDGFRB 307/4885FGFR1 346/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 KDR 256/4885PDGFRB 307/4885FGFR1 346/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 KDR 256/4885PDGFRB 307/4885FGFR1 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.